ストックスクリーナーアプリを入手
102.01
2.13%
2.13
アフターアワーズ：
104.00
1.99
+1.95%
前日終値:
$99.88
開ける：
$100.82
24時間の取引高:
505.40K
Relative Volume:
0.68
時価総額：
$6.11B
収益：
$379.25M
当期純損益:
$-77.34M
株価収益率:
-63.27
EPS:
-1.6122
ネットキャッシュフロー:
$-27.87M
1週間 パフォーマンス:
+3.85%
1か月 パフォーマンス:
+13.98%
6か月 パフォーマンス:
+57.62%
1年 パフォーマンス:
+101.12%
1日の値動き範囲:
$99.80
$103.42
1週間の範囲:
$97.49
$103.42
52週間の値動き範囲:
$36.88
$105.74
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
102.01 | 5.98B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-24 | 開始されました | TD Cowen | Buy |
| 2025-08-11 | 再開されました | Stifel | Buy |
| 2025-05-19 | 再開されました | H.C. Wainwright | Buy |
| 2024-04-17 | 開始されました | Stifel | Buy |
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Mirum Pharmaceuticals Grants Stock Awards to New Employees - Intellectia AI
New Mirum staff get stock grants, some tied to 2027–28 net sales - Stock Titan
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup - ChartMill
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Gem with 14% Upside Potential - DirectorsTalk Interviews
Mirum Pharmaceuticals expands portfolio in rare disease drug focus - Traders Union
Gap Down: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Health Canada approves Livmarli for PFIC and ALGS - The Pharma Letter
Sentiment Review: Is Mirum Pharmaceuticals Inc a turnaround storyFed Meeting & Safe Entry Trade Signal Reports - baoquankhu1.vn
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook - Yahoo Finance
Mirum Pharmaceuticals says Health Canada authorizes Livmarli for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - BioSpace
Mirum Pharmaceuticals Stumbles on Health Canada Approval - Baystreet.ca
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Yahoo Finance
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - AOL.com
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
Mirum Pharmaceuticals (MIRM) Price Target Increased by 10.50% to 116.99 - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $940,856.40 in Stock - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $99,994.40 in Stock - MarketBeat
Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock By Investing.com - Investing.com South Africa
Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock - Investing.com Australia
Mirum Pharma president & COO sells $271k in stock - Investing.com
Mirum Pharma president & COO sells $271k in stock By Investing.com - Investing.com India
Mirum Pharma CEO Peetz sells $941k in shares By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (MIRM): Investor Outlook on a Biotech with a 10.5% Upside Potential - DirectorsTalk Interviews
Y Intercept Hong Kong Ltd Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum doubles down on diversified rare disease strategy - PharmaVoice
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD - Investing.com
Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Atle Fund Management AB - MarketBeat
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - The Motley Fool
EV Market: Is Mirum Pharmaceuticals Inc impacted by rising rates2025 Winners & Losers & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug PreEarnings: Is Tronox Holdings plc impacted by rising ratesIndex Update & Trade Opportunity Analysis - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $123.00 at Morgan Stanley - MarketBeat
Chronic hepatitis D market set for steady growth as pipeline inches forward - The Pharma Letter
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? - Finviz
11 Best Stocks to Buy for Investment - Insider Monkey
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
HC Wainwright Has Negative Outlook of MIRM FY2027 Earnings - MarketBeat
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m By Investing.com - Investing.com UK
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m - Investing.com
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 1,053 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $302,325.17 in Stock - MarketBeat
Jolanda Howe Sells 842 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Christopher Peetz Sells 6,831 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
3 Stocks That May Be Trading Below Estimated Value By Up To 48.2% - simplywall.st
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):